JAK抑制剂在风湿免疫疾病精准治疗中的应用及安全性研究进展

Advances in Application and Safety of JAK Inhibitors in Precision Therapy for Rheumatic Immune Diseases

摘要: Janus激酶抑制剂作为新型小分子靶向药物，通过阻断JAK-STAT信号通路，在风湿免疫疾病的治疗中展现出显著疗效。本文旨在系统综述JAK抑制剂在风湿免疫疾病精准治疗中的应用现状及安全性研究进展。文章首先深入探讨了JAK-STAT信号通路在风湿免疫疾病中的致病机制，分析了第一代与第二代JAK抑制剂的受体选择性差异及其药代动力学特征对精准用药的启示。随后，详细阐述了JAK抑制剂在类风湿关节炎、脊柱关节炎及系统性红斑狼疮等疾病中的临床获益与疗效差异，并对不同疾病背景下疗效异质性的潜在机制进行了批判性分析。最后，重点分析了感染风险、心血管不良事件及恶性肿瘤风险等安全性问题，并针对心血管风险的争议性证据设立了专题机制辨析，并总结了相应的实验室监测策略。现有证据表明，JAK抑制剂疗效确切，但其安全性风险需通过精准的患者筛选与严格的监测管理来平衡，未来的研究方向应聚焦于进一步优化药物选择性，并通过生物标志物指导的前瞻性头对头研究来推动真正的个体化治疗。

Abstract: As a novel class of small-molecule targeted therapies, Janus kinase (JAK) inhibitors have demonstrated significant efficacy in the treatment of rheumatic immune diseases by blocking the JAK-STAT signaling pathway. This review aims to systematically summarize the application status and safety research progress of JAK inhibitors in the precision treatment of rheumatic immune diseases. The article first delves into the pathogenic mechanism of the JAK-STAT signaling pathway in rheumatic immune diseases, analyzing the differences in receptor selectivity between first-generation and second-generation JAK inhibitors and the implications of their pharmacokinetic characteristics for precision medicine. Subsequently, it elaborates on the clinical benefits and efficacy differences of JAK inhibitors in diseases such as rheumatoid arthritis, spondyloarthritis, and systemic lupus erythematosus, with a critical analysis of the mechanisms underlying efficacy heterogeneity across different disease contexts. Finally, it focuses on safety issues such as infection risk, cardiovascular adverse events, and malignancy risk, establishing a dedicated mechanistic discussion on the controversial evidence regarding cardiovascular risk, and summarizing corresponding laboratory monitoring strategies. Current evidence suggests that JAK inhibitors have definite efficacy, but their safety risks need to be balanced through precise patient selection and strict monitoring management. Future research should focus on further optimizing drug selectivity, and promoting truly individualized treatment through biomarker-guided prospective head-to-head trials.